ArticlePneumonia (Nathan Qld.)2025
Existence and relevance of fulminant severe community-acquired pneumonia.
Article in Pneumonia (Nathan Qld.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06516601 (Fulminant Cases Among Severe Community-acquired Pneumonia - an Observational Retrospective Study), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fulminant Cases Among Severe Community-acquired Pneumonia - an Observational Retrospective Study
Who cites it
3 citing papers in PubMed.
- Clinical characteristics and risk factors associated with mortality in patients with severe community-acquired pneumonia in the intensive care unit.Journal of thoracic disease · 2026Article
- Biomarker-guided use of corticosteroids in pneumonia.Pneumonia (Nathan Qld.) · 2026Review
- The Impact of Human Immunodeficiency Virus Co‑Infection on the Pathogen Spectrum and Outcomes of Severe Community‑Acquired Pneumonia: Insights from Metagenomic Next‑Generation Sequencing.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere community-acquired pneumonia (sCAP) is a major contributor to global hospital mortality, with some patients rapidly progressing to death within a few days due to acute respiratory distress syndrome (ARDS), septic shock, or multiorgan failure (MOFS). Despite the significant health burden, these cases remain poorly defined, often overlooked in clinical practice, and insufficiently addressed in existing guidelines.
methodsIn this multicenter retrospective study, we analyzed 1,517 hospitalized patients with sCAP for assessing the incidence of fulminant pneumonia -defined as sCAP leading to death within 7 days from hospital admission- and to identify factors associated with either an increased or reduced risk of unfavorable outcome.
resultsOur findings revealed a 5.9% incidence of fulminant pneumonia, with early death primarily due to ARDS (93%), sepsis (70%), and MOFS (73%). Older age, obesity, diabetes, cardiovascular disease, and elevated serum creatinine were associated with increased risk, while early corticosteroid administration was associated with a significant mortality reduction within seven days, both in the univariate and multivariate analyses (OR 0.22, CI 95% 0.12–0.38, p < 0.001). Baseline respiratory impairment and inflammatory markers were not associated with early mortality.
conclusionThese findings highlight the importance of recognizing sCAP as a time-dependent condition, requiring early identification and treatment of cases at risk for developing fulminant pneumonia at hospital admission. Larger studies and randomized controlled trials are necessary to validate these findings and optimize treatment strategies. CLINICAL
trial registrationClinicalTrials.gov NCT06516601.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.